Innovent Biologics Statistics
Innovent Biologics (IVBXF) Stock Statistics & Valuation Metrics
Total Valuation
Innovent Biologics has a market cap or net worth of $18.98B. The enterprise value is $122.92B.
- Market Cap
- $18.98B
- Enterprise Value
- $122.92B
Share Statistics
Innovent Biologics has 1,747,871,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,747,871,800
- Owned by Insiders
- ―
- Owned by Institutions
- 19.62%
Financial Efficiency
Innovent Biologics’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 2.39%.
- Return on Equity (ROE)
- 0.04
- Return on Assets (ROA)
- 0.02
- Return on Invested Capital (ROIC)
- 2.39%
- Return on Capital Employed (ROCE)
- 0.03
- Revenue Per Employee
- 1.49M
- Profits Per Employee
- 92.94K
- Employee Count
- 8,754
- Asset Turnover
- 0.35
- Inventory Turnover
- 2.34
Valuation Ratios
The current PE Ratio of Innovent Biologics is 101.92. Innovent Biologics’s PEG ratio is 17.07.
- PE Ratio
- 101.92
- PS Ratio
- 8.07
- PB Ratio
- 6.00
- Price to FCF
- 9.67
- Price to Operating Cash Flow
- 9.29
- PEG Ratio
- 17.07
Income Statement
In the last 12 months, Innovent Biologics had revenue of 13.04B and earned 813.57M in profits. Earnings per share was 0.48.
- Revenue
- 13.04B
- Gross Profit
- 10.00B
- Operating Income
- 733.62M
- Pretax Income
- 838.92M
- Net Income
- 813.57M
- EBITDA
- 1.33B
- Earnings Per Share (EPS)
- 0.48
Cash Flow
In the last 12 months, operating cash flow was 13.40B and capital expenditures -397.82M, giving a free cash flow of 13.00B billion.
- Operating Cash Flow
- 13.40B
- Free Cash Flow
- 13.00B
- Free Cash Flow per Share
- 7.53
Dividends & Yields
Innovent Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 10.37%
- Earnings Yield
- 0.98%
Stock Price Statistics
- Beta
- -0.30
- 52-Week Price Change
- -6.70%
- 50-Day Moving Average
- 11.92
- 200-Day Moving Average
- 11.30
- Relative Strength Index (RSI)
- 47.61
- Average Volume (3m)
- 2,384
Important Dates
Innovent Biologics upcoming earnings date is Mar 31, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 25, 2026
- Next Earnings Date
- Mar 31, 2027
- Ex-Dividend Date
- ―
Financial Position
Innovent Biologics as a current ratio of 2.62, with Debt / Equity ratio of 14.55%
- Current Ratio
- 2.62
- Quick Ratio
- 2.47
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- -10.89
- Interest Coverage Ratio
- 9.46
Taxes
In the past 12 months, Innovent Biologics has paid 25.36M in taxes.
- Income Tax
- 25.36M
- Effective Tax Rate
- 0.03
Enterprise Valuation
Innovent Biologics EV to EBITDA ratio is 43.45, with an EV/FCF ratio of 8.49.
- EV to Sales
- 7.08
- EV to EBITDA
- 43.45
- EV to Free Cash Flow
- 8.49
- EV to Operating Cash Flow
- 8.24
Balance Sheet
Innovent Biologics has $20.00B in cash and marketable securities with $2.32B in debt, giving a net cash position of $17.68B billion.
- Cash & Marketable Securities
- $20.00B
- Total Debt
- $2.32B
- Net Cash
- $17.68B
- Net Cash Per Share
- $10.11
- Tangible Book Value Per Share
- $11.16
Margins
Gross margin is 80.96%, with operating margin of 12.02%, and net profit margin of 7.80%.
- Gross Margin
- 80.96%
- Operating Margin
- 12.02%
- Pretax Margin
- 9.82%
- Net Profit Margin
- 7.80%
- EBITDA Margin
- 16.30%
- EBIT Margin
- 12.02%
Analyst Forecast
The average price target for Innovent Biologics is $17.42, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $17.42
- Price Target Upside
- 57.12% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 18
- Revenue Growth Forecast
- 42.21%
- EPS Growth Forecast
- 9.23%
Scores
- Smart Score
- 10
- AI Score
- ―
